TheEdgeResearch
Home / Stocks / HLBBF

H. Lundbeck A/S (HLBBF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$8.75 ▲ +0.00%
Market Cap
$6.94B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.26
52-Wk Range
5.7-9.09
CEO
Charl van Zyl
Country
DK
Currency
USD

H. Lundbeck A/S operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Valby, CR, DK. The stock last traded at $8.75, up 0.00% on the session, giving a market capitalisation of $6.94B. On trailing twelve-month figures it carries a trailing P/E of 14.79, a net margin of 15.5%. Its beta of 0.26 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
14.79
Price / Sales
1.84
Price / Book
2.12
EV / EBITDA
5.79
Gross margin
77.2%
Operating margin
28.3%
Net margin
15.5%
Return on equity
—
Debt / equity
0.31
Current ratio
1.43
Dividend yield
1.9%
Payout ratio
28.3%
Company profile
Exchange
Other OTC
Employees
5,214
IPO date
2022-07-13
Headquarters
Valby, CR, DK
About H. Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

More research on HLBBF
HLBBF technical analysis HLBBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →